Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C12H8O4 |
| Molecular Weight | 216.1895 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=C2C=COC2=CC3=C1C=CC(=O)O3
InChI
InChIKey=BGEBZHIAGXMEMV-UHFFFAOYSA-N
InChI=1S/C12H8O4/c1-14-12-7-2-3-11(13)16-10(7)6-9-8(12)4-5-15-9/h2-6H,1H3
Bergapten, known as 5-methoxypsoralen, a cumarine-derivate compound, presents in many fruits and vegetables. It has shown antitumor effects in a variety of cell types. The key target of bergapten action in breast cancer cells was identified the oncosuppressor gene PTEN (phosphatase tensin homolog deleted from chromosome 10); bergapten by inducing PTEN expression, produces autophagy in breast cancer cells. Besides, bergapten is under investigation in clinical trial phase III for patients with severe generalized atopic dermatitis.
Approval Year
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
82 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1981428/ |
1.2 mg/kg single, oral dose: 1.2 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
BERGAPTEN serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
89 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1981428/ |
1.2 mg/kg single, oral dose: 1.2 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
BERGAPTEN serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
175 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1981428/ |
1.2 mg/kg single, oral dose: 1.2 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
BERGAPTEN serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
108 μg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3994922/ |
1.2 mg/kg single, oral dose: 1.2 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
BERGAPTEN serum | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
322 μg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3994922/ |
1.2 mg/kg single, oral dose: 1.2 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
BERGAPTEN serum | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
1754 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1981428/ |
1.2 mg/kg single, oral dose: 1.2 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
BERGAPTEN serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
1757 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1981428/ |
1.2 mg/kg single, oral dose: 1.2 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
BERGAPTEN serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
3282 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1981428/ |
1.2 mg/kg single, oral dose: 1.2 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
BERGAPTEN serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
276 μg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3994922/ |
1.2 mg/kg single, oral dose: 1.2 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
BERGAPTEN serum | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
942 μg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3994922/ |
1.2 mg/kg single, oral dose: 1.2 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
BERGAPTEN serum | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
Doses
| Dose | Population | Adverse events |
|---|---|---|
1.2 mg/kg 1 times / day multiple, oral Studied dose Dose: 1.2 mg/kg, 1 times / day Route: oral Route: multiple Dose: 1.2 mg/kg, 1 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
Other AEs: Vomiting... |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Vomiting | 4% | 1.2 mg/kg 1 times / day multiple, oral Studied dose Dose: 1.2 mg/kg, 1 times / day Route: oral Route: multiple Dose: 1.2 mg/kg, 1 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
PubMed
| Title | Date | PubMed |
|---|---|---|
| The psoralens adversely affect reproductive function in male wistar rats. | 2001 Mar-Apr |
|
| Inhibition of human CYP3A4 activity by grapefruit flavonoids, furanocoumarins and related compounds. | 2001 Sep-Dec |
|
| Chalcones and other constituents of Dorstenia prorepens and Dorstenia zenkeri. | 2002 Apr |
|
| Effects of storage conditions on furocoumarin levels in intact, chopped, or homogenized parsnips. | 2002 Apr 24 |
|
| Constituents of the fruits and leaves of Euodia daniellii. | 2002 Dec |
|
| Bullous phytophotodermatitis associated with high natural concentrations of furanocoumarins in limes. | 2002 Mar |
|
| Validation of a microdialysis-gas chromatographic-mass spectrometric method to assess 8-methoxypsoralen in psoriatic patient dermis. | 2002 Nov 15 |
|
| Determination of 5-methoxypsoralen in human serum. | 2002 Oct 15 |
|
| Tea: not immoral, illegal, or fattening, but is it innocuous? | 2002 Sep 14 |
|
| In vivo effect of 5- and 8-methoxypsoralens and cimetidine on R,S-warfarin metabolism in rat. | 2002 Sep-Oct |
|
| Effect of psoralens on Fenton-like reaction generating reactive oxygen species. | 2003 |
|
| Assessing the separation of neutral plant secondary metabolites by micellar electrokinetic chromatography. | 2003 Jul 4 |
|
| Antibacterial coumarins from Angelica gigas roots. | 2003 Jun |
|
| Effect of 5-methoxypsoralen (5-MOP) on cell apoptosis and cell cycle in human hepatocellular carcinoma cell line. | 2003 Jun |
|
| Coumarins from Cnidium monnieri (L.) and their proliferation stimulating activity on osteoblast-like UMR106 cells. | 2004 Aug |
|
| Preparative isolation and purification of bergapten and imperatorin from the medicinal plant Cnidium monnieri using high-speed counter-current chromatography by stepwise increasing the flow-rate of the mobile phase. | 2004 Dec 17 |
|
| Prenylated flavonoids, monoterpenoid furanocoumarins and other constituents from the twigs of Dorstenia elliptica (Moraceae). | 2004 Jan |
|
| Furanocoumarin biosynthesis in Ammi majus L. Cloning of bergaptol O-methyltransferase. | 2004 Mar |
|
| Citrus aurantium, an ingredient of dietary supplements marketed for weight loss: current status of clinical and basic research. | 2004 Sep |
|
| Accumulation of biologically active furanocoumarins in agitated cultures of Ruta graveolens L. and Ruta graveolens ssp. divaricata (Tenore) Gams. | 2005 Aug |
|
| Accumulation of biologically active furanocoumarins in Ruta graveolens ssp. divaricata (Tenore) Gams in vitro culture. | 2005 Jan |
|
| Internet-based search of randomised trials relevant to mental health originating in the Arab world. | 2005 Jul 26 |
|
| Post-stress metabolism involves umbelliferone production in anthocyanin-producing and nonproducing cells of Glehnia littoralis suspension cultures. | 2005 Jun |
|
| Two new sesquiterpenoids and anti-HIV principles from the root bark of Zanthoxylum ailanthoides. | 2005 Nov 1 |
|
| Effects of 5-methoxypsoralen (5-MOP) on arylamine N-acetyltransferase activity in the stomach and colon of rats and human stomach and colon tumor cell lines. | 2005 Nov-Dec |
|
| Remarkable substrate-specificity of CYP6AB3 in Depressaria pastinacella, a highly specialized caterpillar. | 2006 Apr |
|
| A method for quantitative determination of furanocoumarins in capsules and tablets of phytochemical preparations. | 2006 Apr |
|
| [Studies on chemical constituents from roots of Peucedanum praeruptorum II]. | 2006 Aug |
|
| [Studies on chemical constituents in roots of Heracleum rapula]. | 2006 Feb |
|
| Cytochrome P450-mediated metabolism of xanthotoxin by Papilio multicaudatus. | 2006 Mar |
|
| Efficacy of 8-methoxypsoralen vs. 5-methoxypsoralen plus ultraviolet A therapy in patients with mycosis fungoides. | 2006 Mar |
|
| Apiaceous vegetable constituents inhibit human cytochrome P-450 1A2 (hCYP1A2) activity and hCYP1A2-mediated mutagenicity of aflatoxin B1. | 2006 Sep |
|
| Use of the yeast Saccharomyces cerevisiae as a pre-screening approach for assessment of chemical-induced phototoxicity. | 2006 Sep |
|
| Inhibition on human liver cytochrome P450 3A4 by constituents of fennel (Foeniculum vulgare): identification and characterization of a mechanism-based inactivator. | 2007 Dec 12 |
|
| Ethnoveterinary medicines used for ruminants in British Columbia, Canada. | 2007 Feb 26 |
|
| Esterase inhibition by grapefruit juice flavonoids leading to a new drug interaction. | 2007 Jul |
|
| Quality assessment of Rhizoma et Radix Notopterygii by HPTLC and HPLC fingerprinting and HPLC quantitative analysis. | 2007 Jul 27 |
|
| Herbal medicine today: clinical and research issues. | 2007 Sep |
|
| [Simultaneous determination of 8-methoxypsoralen and 5-methoxypsoralen in cosmetics using LC-MS/MS]. | 2007 Sep |
|
| [Simultaneous determination of 5 active components in Fructus Cnidii by HPLC]. | 2007 Sep |
|
| Coumarins from Peucedanum luxurians. | 2007 Sep |
|
| Central role of mitochondria and p53 in PUVA-induced apoptosis in human keratinocytes cell line NCTC-2544. | 2008 Feb 15 |
|
| Induction of gamma-globin mRNA, erythroid differentiation and apoptosis in UVA-irradiated human erythroid cells in the presence of furocumarin derivatives. | 2008 Feb 15 |
|
| In vivo methods for the assessment of topical drug bioavailability. | 2008 Jan |
|
| Enhancement of bone morphogenetic protein-2 expression and bone formation by coumarin derivatives via p38 and ERK-dependent pathway in osteoblasts. | 2008 Jan 28 |
|
| Irritant and cytotoxic coumarins from Angelica glauca Edgew roots. | 2008 Jan-Feb |
|
| Identification of Ruta graveolens L. metabolites accumulated in the presence of abiotic elicitors. | 2008 Jan-Feb |
|
| Effective biotic elicitation of Ruta graveolens L. shoot cultures by lysates from Pectobacterium atrosepticum and Bacillus sp. | 2008 Mar |
|
| In vitro antiplasmodial activity of extract and constituents from Esenbeckia febrifuga, a plant traditionally used to treat malaria in the Brazilian Amazon. | 2008 May |
|
| Application of chitin and chitosan as elicitors of coumarins and fluoroquinolone alkaloids in Ruta graveolens L. (common rue). | 2008 Oct |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT00533195
1,2 mg/kg 2 hours before UVA irradiation p.o. 3 times weekly for 5 weeks
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26188800
Bone marrow stromal cells (BMSCs) were cultured in osteogenic induction medium with the addition of bergapten for 2 weeks. The concentrations of bergapten used were 0.1, 1, and 10 μmol/L in vitro. Bergapten promotes the expression of alkaline phosphatase (ALP) by BMSCs in vitro in a dose-dependent manner, as revealed by ALP staining.
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WHO-ATC |
D05BA03
Created by
admin on Mon Mar 31 18:12:33 GMT 2025 , Edited by admin on Mon Mar 31 18:12:33 GMT 2025
|
||
|
WHO-VATC |
QD05BA03
Created by
admin on Mon Mar 31 18:12:33 GMT 2025 , Edited by admin on Mon Mar 31 18:12:33 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
CHEMBL24171
Created by
admin on Mon Mar 31 18:12:33 GMT 2025 , Edited by admin on Mon Mar 31 18:12:33 GMT 2025
|
PRIMARY | |||
|
3466
Created by
admin on Mon Mar 31 18:12:33 GMT 2025 , Edited by admin on Mon Mar 31 18:12:33 GMT 2025
|
PRIMARY | |||
|
4FVK84C92X
Created by
admin on Mon Mar 31 18:12:33 GMT 2025 , Edited by admin on Mon Mar 31 18:12:33 GMT 2025
|
PRIMARY | |||
|
DB12216
Created by
admin on Mon Mar 31 18:12:33 GMT 2025 , Edited by admin on Mon Mar 31 18:12:33 GMT 2025
|
PRIMARY | |||
|
18293
Created by
admin on Mon Mar 31 18:12:33 GMT 2025 , Edited by admin on Mon Mar 31 18:12:33 GMT 2025
|
PRIMARY | |||
|
207-604-5
Created by
admin on Mon Mar 31 18:12:33 GMT 2025 , Edited by admin on Mon Mar 31 18:12:33 GMT 2025
|
PRIMARY | |||
|
484-20-8
Created by
admin on Mon Mar 31 18:12:33 GMT 2025 , Edited by admin on Mon Mar 31 18:12:33 GMT 2025
|
PRIMARY | |||
|
2355
Created by
admin on Mon Mar 31 18:12:33 GMT 2025 , Edited by admin on Mon Mar 31 18:12:33 GMT 2025
|
PRIMARY | |||
|
95437
Created by
admin on Mon Mar 31 18:12:33 GMT 2025 , Edited by admin on Mon Mar 31 18:12:33 GMT 2025
|
PRIMARY | |||
|
15842
Created by
admin on Mon Mar 31 18:12:33 GMT 2025 , Edited by admin on Mon Mar 31 18:12:33 GMT 2025
|
PRIMARY | RxNorm | ||
|
C022909
Created by
admin on Mon Mar 31 18:12:33 GMT 2025 , Edited by admin on Mon Mar 31 18:12:33 GMT 2025
|
PRIMARY | |||
|
1065345
Created by
admin on Mon Mar 31 18:12:33 GMT 2025 , Edited by admin on Mon Mar 31 18:12:33 GMT 2025
|
PRIMARY | |||
|
100000078282
Created by
admin on Mon Mar 31 18:12:33 GMT 2025 , Edited by admin on Mon Mar 31 18:12:33 GMT 2025
|
PRIMARY | |||
|
3021
Created by
admin on Mon Mar 31 18:12:33 GMT 2025 , Edited by admin on Mon Mar 31 18:12:33 GMT 2025
|
PRIMARY | |||
|
DTXSID1025560
Created by
admin on Mon Mar 31 18:12:33 GMT 2025 , Edited by admin on Mon Mar 31 18:12:33 GMT 2025
|
PRIMARY | |||
|
SUB12695MIG
Created by
admin on Mon Mar 31 18:12:33 GMT 2025 , Edited by admin on Mon Mar 31 18:12:33 GMT 2025
|
PRIMARY | |||
|
m2430
Created by
admin on Mon Mar 31 18:12:33 GMT 2025 , Edited by admin on Mon Mar 31 18:12:33 GMT 2025
|
PRIMARY | Merck Index | ||
|
BERGAPTEN
Created by
admin on Mon Mar 31 18:12:33 GMT 2025 , Edited by admin on Mon Mar 31 18:12:33 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)